X

Trial Profile

A Phase I/IIa Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IAH 0968 (Primary) ; Cisplatin; Gemcitabine
Indications Advanced breast cancer; Biliary cancer; Colon cancer; Gastric cancer; HER2 positive breast cancer; Pancreatic cancer; Rectal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors SUNHO (China) BioPharmaceutical

Most Recent Events

18 Feb 2024 Planned End Date changed from 6 Dec 2024 to 31 Mar 2025.
18 Feb 2024 Planned primary completion date changed from 6 Dec 2023 to 31 Dec 2024.
24 Jul 2023 Planned End Date changed from 1 Jun 2024 to 6 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com